Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

NCT01919619 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Leukemia
Lymphoma
Plasma Cell Myeloma
T-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Ipilimumab
DRUG: Lenalidomide

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]